2024 Documentation Pharmaceutical Companies 
STAT
MARCH 18, 2024
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…
Viseven
JULY 10, 2024
As a specialized field, medical writing encompasses the creation of various documents, from regulatory submission documents to medical journal articles, that convey critical medical knowledge to diverse audiences. This crucial role explains why the market is projected to grow at a CAGR of 10% from 2024 to 2032, potentially reaching $2.57
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
FEBRUARY 1, 2024
Even though patients are on existing [statins] that are well-documented and most likely safe and effective, there are many patients who still have cardiovascular disease, the leading cause of death” We are recognising now is that there is great data on how to reduce risk by applying lipid lowering therapy like statins.
The Checkup by Singlecare
MARCH 10, 2025
Compounded semaglutide is made by special compounding pharmacies rather than pharmaceutical companies. Your healthcare provider will need to provide documentation to support your request for coverage. The medication is available in both brand-name and compounded forms, although the compounded forms are not FDA approved.
European Pharmaceutical Review
JULY 4, 2024
2 The prerequisite to present statistically significant evidence for having efficacies of clinical relevance is crucial because FDA requires “adequate and well-controlled” multicentre clinical studies on any new drug candidate to document and support its safety and efficacy, and imposes the maximum level of scrutiny prior to approval.
The Checkup by Singlecare
APRIL 5, 2024
Pharmaceutical companies typically only provide prescription drug samples to healthcare providers, who keep them in the office for patients to use. Per Bonza, that paperwork might include a documented Type 2 diabetes diagnosis, medical test confirmation, and evidence of persistently elevated A1C despite oral therapy.
ISPE
JULY 6, 2023
1 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Q13 Development Timeline The process of drafting the new guidance document was initiated in earnest in November 2018 when the concept paper 2 and business plan were endorsed.
Expert insights. Personalized for you.
145 
Let's personalize your content